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Framing overdiagnosis in breast screening:
a qualitative study with Australian experts
Lisa M. Parker1*, Lucie Rychetnik2 and Stacy Carter1
Abstract
Background: The purpose of this study was to identify how the topic of overdiagnosis in breast cancer screening
is framed by experts and to clarify differences and similarities within these frames in terms of problems, causes,
values and solutions.
Methods: We used a qualitative methodology using interviews with breast screening experts across Australia and
applying framing theory to map and analyse their views about overdiagnosis. We interviewed 33 breast screening
experts who influence the public and/or policy makers via one or more of: public or academic commentary; senior
service management; government advisory bodies; professional committees; non-government/consumer
organisations. Experts were currently or previously working in breast screening in a variety of roles including clinical
practice, research, service provision and policy, consumer representation and advocacy.
Results: Each expert used one or more of six frames to conceptualise overdiagnosis in breast screening. Frames are
described as: Overdiagnosis is harming women; Stop squabbling in public; Don’t hide the problem from women;
We need to know the overdiagnosis rate; Balancing harms and benefits is a personal matter; and The problem is
overtreatment. Each frame contains a different but internally coherent account of what the problem is, the causes
and solutions, and a moral evaluation. Some of the frames are at least partly commensurable with each other;
others are strongly incommensurable.
Conclusions: Experts have very different ways of framing overdiagnosis in breast screening. This variation may
contribute to the ongoing controversy in this topic. The concept of experts using different frames when thinking
and talking about overdiagnosis might be a useful tool for those who are trying to negotiate the complexity of
expert disagreement in order to participate in decisions about screening.
Background
Overdiagnosis in breast screening has become a highly
contentious issue and source of strong disagreement
amongst experts. In this paper we use the term “overdi-
agnosis” to mean the diagnosis through mammographic
screening of an asymptomatic breast condition that is
non-progressive or so slowly progressive that it would
not otherwise have come to the patient’s attention in her
lifetime, and where this diagnosis provides no net benefit
to the patient [1]. The possibility of overdiagnosis in
breast screening was acknowledged from its early days
of use. The idea that breast screening might lead to the
detection of lesions that are “morphologically malignant
but clinically benign” was raised as early as the 1970s
([2], p490). Later it was also recognised that mammo-
graphic screening would uncover a significant number
of in-situ cancers, at least some of which “might not
have entered an invasive phase during their lifetime”
([3], p14) and would likely fall into the category of over-
diagnosis. Despite this, there was limited controversy
about overdiagnosis when breast screening programs
were being introduced in many Western countries dur-
ing the 1980s and 1990s. This may have been partly be-
cause of poor outcomes from treatment of symptomatic
breast cancers and the evidence-based promise of a 30 %
reduction in population breast cancer mortality.
Since that time, however, the evidence-based estimates
of the mortality benefit from breast screening have been
revised and reduced [4, 5]. In addition, improvements in
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breast cancer treatment are likely to have further reduced
the potential impact of screening in the modern Western
setting [5, 6]. These developments have fostered a growing
interest amongst breast screening experts about the
significance of overdiagnosis, which is now a topic of
major international concern [7–9].
Researchers and clinicians present many different views
about overdiagnosis, and focus on different problems and
solutions, including: preventing overdiagnosis harm [10];
communicating with women about overdiagnosis [11–13];
and quantification of overdiagnosis [14–16]. There are
also big differences of opinion within these topics. Under-
standing how and why experts form their opinions about
this complex issue, and sometimes arise at opposing
views, would add to our understanding of the current pro-
cesses for early detection in breast cancer and assist those
who seek to contribute to mammography screening pol-
icy, as well as those participating in consumer decisions
about screening.
We conducted a detailed qualitative study of the views
and opinions of Australian breast screening experts on a
range of topics related to mammography screening. We
used a framing approach to map and analyse experts’
views on the issue of overdiagnosis. Framing describes
the particular mind-set through which a topic is under-
stood. The framing of an issue determines how the prob-
lem is conceived, what information is selected and the
value judgements that are made. Different frames in-
corporate different, apparently self-evident, strategies to
solve the perceived problem [17, 18]. Frames can be
used in politics or by institutions to convey a particular
message or point of view [19]. Frames are not only used
as deliberate tools: they are also used by individuals,
often unconsciously, as a way of thinking about and
making sense of a complex topic. Framing theory is par-
ticularly well-suited to the study of overdiagnosis be-
cause it allows for a detailed examination of different
viewpoints held, and used, by experts about this conten-
tious topic. We present our analysis of how experts
framed the topic of overdiagnosis in breast screening.
Our research questions were:
 How do Australian breast screening experts frame
overdiagnosis?
 How do those frames present the problems, causal
elements, value judgements and solutions relevant
to overdiagnosis?
Methods
This study is part of a larger Australian National Health
and Medical Research Council (NHMRC) funded project
examining ethical issues in cancer screening in Australia
[20]. One component of the larger project was a qualita-
tive study of contemporary issues in breast cancer
screening, using semi-structured interviews with influen-
tial breast screening experts. This paper is reporting on
one aspect of this breast screening study. We defined
“influential experts” as people working or researching in
breast screening who influence the public, primary care
practitioners and/or policy makers by engaging in one or
more of: media commentary; academic or lay publications
and presentations; senior service delivery management;
membership of government advisory bodies, professional
committees and/or non-government/consumer organisa-
tions related to breast screening. We sampled purposively
from this population, seeking to obtain a wide diversity of
views by inviting participants with a range of publicly
aired positions [21]. We reasoned that perspectives on
screening might be associated with professional back-
grounds so we ensured that we included experts with a
range of roles and responsibilities. See Table 1 for further
participant details.
We identified potential participants by scanning aca-
demic and lay literature on breast screening, examining
personnel lists on websites of government or non-
Table 1 Characteristics of experts
Participants 33 (Brackets contain number of experts who were invited
but did not-participate; 13)
Professional role* Clinicians^ 15 (3)
• Oncologists 3 (1)
• Surgeons 4 (0)
• Breast physicians 1 (2)
• Radiologists 2 (0)
• Radiation oncologists 2 (0)
• Pathologists 3 (0)
• Others [not otherwise specified; NOS)]
0 (1)
Non-clinical researchers 14 (3)
• Epidemiologists/biostatisticians 9 (1)
• Others [NOS] 5 (1)
Administrators/managers 6 (2)
Advocacy leaders 6 (7)
• Consumers working in advocacy 3 (6)
• Clinicians/researchers working in
advocacy 3 (1)
Public stance on breast
screening+
Supportive 16 (9)
Mostly supportive# 3 (1)
Critical 6 (0)
Unknown to researchers 8 (3)
*note that some experts held more than one professional role
^Most clinicians engaged in research to a greater or lesser extent
+We loosely categorised potential interviewees as being “supportive”, “mostly
supportive” or “critical” about breast screening based on publicly
available commentary
#Broadly supportive of breast screening but with selected concerns about one
or more elements of the program
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government advisory and advocacy bodies involved in
breast screening, and following up suggestions from
colleagues and participants. We used information in
the public domain to contact experts by email. Forty-
six experts were contacted, and 33 (17 male, 16 female)
participated in the study. Thirteen people either did not
wish to participate (3), did not respond (9) or were un-
able to participate in the time available (1). We had a
low response rate from senior community advocacy fig-
ures. Speculatively, this may have been due to a higher
turnover of staff in these (largely volunteer) positions
than in other professional roles. That is, the individuals
may no longer have been contactable at the email
addresses that we had access to. We continued sampling
until we had good representation of a range of profes-
sional roles and until we reached thematic saturation in
our analysis [22].
We used an interview format for in-depth exploration
of the views and reasoning of experts. LP conducted semi-
structured interviews from October 2012 to October
2013, meeting in the participant’s or her own workplace,
or talking over telephone if unable to meet in person. The
interviews lasted between 39 and 105 min (average
66 min) and there was no observed difference between
face to face and telephone interviews in terms of quality
or length [23]. At the beginning of each interview, LP dis-
cussed her interest in the topic with the expert, explaining
that she was a medical practitioner with clinical experi-
ence in breast screening, currently undertaking doctoral
studies in cancer-screening ethics. She clarified that the
purpose of the interviews was to glean the range of opin-
ions amongst Australian experts about breast screening.
The interviews drew loosely on a set of core questions de-
signed to draw out the participant’s views. We also sought
to tailor each interview to the particular expertise and in-
terests of the participants, and explored the leads and
topics that arose throughout the discussion [22, 24]. We
encouraged the participants to talk about overdiagnosis,
asking generally for interviewees’ views on this topic, with-
out pre-empting ideas about what might be considered
important. We only pursued particular lines of enquiry
about controversial elements – as informed by the litera-
ture – if this flowed on from preceding comments of the
participant. An additional file outlines sample interview
questions (see Additional file 1).
The interviews were taped, transcribed and de-
identified. We used an inductive analytic methodology,
developing a set of categories that captured the most
important views and values in the experts’ comments.
Each interview was read repeatedly and coded in detail
to capture views and values relevant to overdiagnosis.
The analysis was conducted as an iterative process com-
prising detailed coding of individual transcripts (LP) and
discussion and revision of the findings in group analysis
meetings (all authors). We used framing theory to organise
and understand different ways that experts thought about
overdiagnosis, identifying the dominant frames in use and
categorising important elements of each frame in terms of
problems, causes, solutions and moral evaluation [18].
Ethics approval was granted from the Cancer Institute
NSW Population & Health Services Research Ethics Com-
mittee [HREC/12/CIPHS/46] and the University of Sydney
Human Research Ethics Committee [#15245]. All partici-
pants gave individual consent to be interviewed, and were
free to withdraw from the study at any stage.
Results
We identified six frames that Australian breast screening
experts used with regard to overdiagnosis (Table 2).
Frame 1: overdiagnosis is harming women
“I would like to see breast cancer eradicated too but
not at the expense of … potentially treating them with
serious treatments for a condition that maybe didn’t
need to be found in the first place… To me, it’s all
about how do we run this program in a way that
minimises the harm … without losing the benefit.”
(Expert #33, clinician)
Experts who used this frame were passionate about
the topic of overdiagnosis in breast screening and saw
it as a major threat to the wellbeing of women. The
frame emphasised both quantity and quality of harm.
Harm quantity was described in terms of the high num-
ber of overdiagnosed cases compared to the number of
lives saved by screening. Harm quality was discussed by
highlighting the serious negative impact from each case of
overdiagnosis, including both the psychological impact of
a breast cancer diagnosis on a woman and her female
relatives (for whom it has perceived risk implications), and
the short and long term impact of unnecessary treatment
on lifestyle and physical health. This framing of overdiag-
nosis as a serious problem was grounded in a strong com-
mitment to avoiding harm in any public health program.
This frame encompassed two categories of solution.
Experts who were enthusiastic about the potential benefits
of screening suggested reducing overdiagnosis through a
targeted, personalised screening program, matching rec-
ommended screening frequency to breast cancer risk as
determined by factors such as breast density. This would
enable the population to simultaneously retain benefits of
screening and reduce harms. Experts who were more scep-
tical about the benefits accruing from breast screening
preferred a more extreme solution: reducing overdiagnosis
by decreasing overall breast screening participation. How-
ever, they assumed that cessation of public funding for the
program was politically unlikely, and promoted more
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realistic solutions such the removal of governmental pro-
motions and personalised screening invitations.
Frame 2: stop squabbling in public about overdiagnosis
“I feel that it’s unwarranted … when … the
[overdiagnosis] debate is mentioned in a way that it
might deter people from actually participating in
screening. I think that’s really counterproductive… The
debate should be managed in a way that it’s not
inadvertently discouraging screening.” (Expert #10,
consumer advocate)
This frame centres on the negative publicity generated
by overdiagnosis discussions and the decrease in breast
screening participation that might ensue. Underlying this
concern is a firm belief in the net benefit of breast
screening and a strong desire to have women avail them-
selves of life-saving opportunities. The frame delivers a
choice between life and overdiagnosis: “saving a life is
more important than the harm that’s caused in damaging
normal breasts.” (Expert #3, clinician). Experts using this
frame regarded overdiagnosis as a minor problem, for sev-
eral reasons. Firstly, and most commonly, it was seen as
an inevitable part of screening, particularly breast screen-
ing where cancer growth is variable and unpredictable.
Secondly, the number of overdiagnosed cases was consid-
ered low relative to the total number of breast cancers
picked up through the program. Finally, the harm associ-
ated with each overdiagnosed case was seen as low. This
was justified in several ways: 1) individual women could
not know whether or not their cancer was a case of over-
diagnosis; 2) women (allegedly) disregarded the concept of
overdiagnosis when considering treatment options; and 3)
treatment for small, low-grade cancers (ie those most
likely to be cases of overdiagnosis) was viewed as relatively
benign. In addition to the lack of harm, the frame
highlighted possible benefits from overdiagnosis. Al-
though, by definition, an overdiagnosed cancer will not it-
self threaten a woman’s life, experts suggested that as the
Table 2 Overdiagnosis frames adopted by Australian breast screening experts
Frame Defining the problem The reasons for the problem Value judgement Proposed or implied solution
1. Overdiagnosis is
harming women
Breast screening is resulting in
significant harm to women
because of overdiagnosis
The harms associated with
overdiagnosis are significant in
both quantity and quality
Breast screening programs
should pay more attention to
avoiding the serious harms of
overdiagnosis
Reduce overdiagnosis either by
performing targeted screening
or by reducing screening
overall
2. Stop
squabbling in
public about
overdiagnosis
The public discussion of
overdiagnosis is generating
negative publicity which may
reduce breast screening
participation & is therefore a
disservice to women
Exaggeration of harms in
public debates is causing
confusion amongst women
and threatening participation
rates.
Breast screening
commentators should give
priority to delivering health
benefits (saving lives)
Confine discussion about
overdiagnosis to academic
circles only, avoiding public
confusion
3. Don’t hide the
overdiagnosis
problem from
women
The breast screening program
is not facilitating informed
choice amongst women
There is a deliberate lack of
communication about
overdiagnosis from breast
screening providers because
of a desire to maximise breast
screening participation
Breast screening should give
absolute priority to
promoting autonomy via
informed choice
Fully inform women about
overdiagnosis
4. We need to
know the
overdiagnosis rate
It is not clear how much
overdiagnosis is present in
breast screening
There is huge variation in
overdiagnosis rates due to
different methodologies and/
or data sets; differences in the
way overdiagnosis figures are
presented hampers
interpretation by non-
epidemiologists
Overdiagnosis research
should be more rigorous,
robust and consistent
Commit to reaching a
consensus on appropriate
methodology & the way we
report the figures
5. Balancing
harms and
benefits is a
personal matter
It is not clear how to compare
the harms & benefits of breast
screening
It is impossible for experts to
definitively compare harms &
benefits because they are
qualitatively different
Breast screening decision
making should be guided by
a consumer-orientated
process, which takes into ac-
count public attitudes to
harms and benefits
Use deliberative methods to
inform policy decisions;
support individual consumers
to make personal decisions
about participation
6. The problem is
overtreatment
Breast screening is resulting in
overdiagnosis which leads to
overtreatment of some
women
Management of some women
with cancer is sometimes
unnecessarily aggressive
because we don’t know
enough about the natural
history of screen detected
lesions
While it is important that
screening continues to save
lives, we should seek ways to
reduce harms from
unnecessary (over) treatment
Ongoing education for
pathologists; renaming non-
invasive lesions; research into
prognostic biomarkers, targeted
treatments & less aggressive
management regimes; patient
centred care
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woman would be at increased risk of a second breast can-
cer she would benefit from being identified and treated
with tamoxifen.
In this frame, personal autonomy and informed
choice were important values in healthcare. However
experts rejected the idea that stopping ‘squabbling in
public’ might conflict with respecting womens’ auton-
omy. Their central concern was not so much that
overdiagnosis was mentioned, but that overdiagnosis
was invariably (mis) represented as an important
harm:
“Harm is a term that’s been developed by
academics, along academic lines… There’s a
possibility of over diagnosis … it’s not very much …
you shouldn’t call that harmful.” (Expert #17,
consumer advocate)
Some experts used this frame with the view that in-
formed choice was an unattainable goal, because overdi-
agnosis in breast screening is just so complex:
“There’s all this business of informed consent. Well,
frankly, I think it’s for the birds. I think it’s a very
difficult thing for people to have informed consent.
When people argue a lot, you know, people that are
informed, supposedly, argue, I don’t know how you
give informed consent. It’s very difficult for the
average layperson to understand.” (Expert #9,
clinician)
There was also moral condemnation of the particular
impact that negative publicity has upon disadvantaged
women. This group was presented as being particularly
likely to be confused by public debates, and vulnerable
to screening disengagement:
“There’s probably people in the [suburbs of lower
socioeconomic status] who stop going to screening.
Because they’re not as sophisticated … and they come
from non-English speaking backgrounds. The message
they get is that screening is not needed… It’s okay if
you’re in the [suburbs of higher socioeconomic status]
because you’ll keep coming anyway.” (Expert #29,
clinician)
In this frame, appropriate solutions focussed on pre-
venting a fall in participation rates. They included:
avoiding any implication that overdiagnosis is a harm;
keeping discussions confined to academic circles; and
informing women about overdiagnosis only when at-
tendance is secured (such as at the point of mammo-
gram or after diagnosis).
Frame 3: don’t hide the overdiagnosis problem from
women
“We should absolutely tell people, ‘These are the
benefits, these are the harms’; and some people say
that public health benefits should be what we are
aiming for, but for me I think you absolutely cannot
compromise on telling people. It’s just not something
I’m prepared to do.” (Expert #23, researcher NOS)
This frame centres on the lack of communication
about overdiagnosis from screening providers to women.
Experts acknowledged that while some women prefer a
simple advisory message about breast screening, others
want an informed decision making process, with the
readily available and easily-understood information. The
current lack of communication about overdiagnosis was
presented as a deliberate strategy by screening providers
to avoid risking a decline in participation. In this frame,
informed choice was an absolute right for individual
women, taking priority over the delivery of population
health benefits.
The solution was to make information about overdiag-
nosis available to women, despite the inherent complex-
ities in the topic and the tension with trying to encourage
participation:
“I agree with you that the experts can’t agree and how
do you talk to women about it, and it is a very
complex area and hard to talk about, but clearly an
important issue in the context of screening… I think
you have to share with women your uncertainty.”
(Expert #25, epidemiologist)
This frame accommodated a variety of solutions ranging
from detailed publicising of overdiagnosis information in
every screening pamphlet and advertisement, to making
detail of possible harms from screening available upon re-
quest. In this frame provision of information could co-
exist alongside government promotion of screening.
Frame 4: we need to know the overdiagnosis rate
“There is a recognition that there are tumours found
that are either frankly non-progressive or are likely to
progress so slowly they don’t matter. I don’t think too
many people would say, ‘Well that wouldn’t exist at
all’. The argument is over how much and the scale of
that.” (Expert #22, epidemiologist)
In this frame, the main problem was overdiagnosis
measurement and quantification. Experts spoke of overdi-
agnosis as being of indeterminate significance because of
uncertainty about the overdiagnosis rate. They saw the
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wide range of estimates as a central conundrum, possibly
explainable by different methodologies and variable data
sets. A subsidiary problem was the inconsistent presenta-
tion of overdiagnosis figures, variably portrayed as accept-
ably low by comparing with the (large) number of cancers
diagnosed, or as unacceptably high by comparing with the
(smaller) number of lives saved by screening. This made it
difficult to compare studies and understand the implica-
tions of overdiagnosis. In this frame sloppy research
methods aimed at generating quick or provocative publi-
cations were a particular problem, eliciting strong disap-
proval. The first step to solving this quantitative problem
would be to reach consensus on the most reliable and ro-
bust ways to calculate and present overdiagnosis.
Frame 5: balancing harms and benefits is a personal
matter
“Descriptively they’re quite different … I don’t think
there is any formula for the balance… It’s very
subjective of the balance of disparate outcomes.”
(Expert #20, clinician)
Through this frame, the problem was comparing harms
and benefits of breast screening. Experts discussed both
overdiagnosis harms and mortality benefits accruing from
breast screening. They suggested that while each are likely
to be important to women, current estimates about their
rates meant that harms and benefits were closely balanced;
in this situation, qualitative differences between the two
made it impossible for experts to draw exact conclusions
about where and when equipoise arose. In this frame, such
uncertainty required that the public should assist with de-
cision making. Experts explained that since individual atti-
tudes to harms and benefits would determine what was
perceived as the net outcome of screening, the process of
decision making needed consumer input: it was insuffi-
cient to rely on pre-determined program values or system
priorities. The frame encompassed two possible solutions.
Some experts discussed seeking public assistance with de-
cision making at the policy level, using a deliberative
process such as a citizens’ jury to make a ruling about the
balance between benefits and harms:
“I believe that for a lot of screening things there should
be a community jury. There are some things that are
obvious, that we can just proceed with them, but other
things where there’s a balance between the benefits
and harms, I think we need some sort of deliberative
democracy process.” (Expert #21, researcher NOS)
Others spoke of more explicit attempts to achieve in-
formed consumer decision making, encouraging women
to consider the net value of screening for themselves as
individuals. They suggested screening participation deci-
sions should be based on women’s personal priorities rather
than potentially coercive input from screening providers.
Frame 6: the problem is overtreatment
“I don’t really believe in overdiagnosis as such. I mean,
I think there’s over treatment … Finding it is not the
issue. Treating – how it’s treated is the issue, as I see
it.” (Expert #9, clinician and provider)
The final frame through which overdiagnosis was under-
stood purposefully separated the treatment process from
the screening process, and presented the problem as arising
from treatment decisions. Several causal elements for the
growing problem of overtreatment were presented: some
experts spoke of the increasing sensitivity of radiological
equipment, meaning that more and more lesions were
identified. Others noted that diagnostic criteria for certain
pathological entities were vague, and “not … easy to get
inter-observer agreement on.” (Expert #28, clinician) They
discussed resulting disagreements about the threshold for
atypia, with tendencies amongst some pathologists for
‘overcalling’ cancer so that benign changes were more likely
to be named and treated as borderline lesions. Finally,
experts commented on the limited research around natural
history and management guidelines for low-risk lesions.
Expert #28, (clinician) noted that, “a lot of those guidelines
are based on reviews of data which are not robust” and sug-
gested that they were instead driven by clinicians’ observer
bias and accepted by women with high levels of anxiety and
fear. Women with low-risk lesions were perceived as under-
going aggressive treatments while, “you really wonder
whether any of it was actually necessary.” (Expert #13,
clinician)
In this frame, both mortality benefit and harm avoid-
ance were valued. Thus appropriate solutions in this frame
maintained current screening parameters, and only altered
downstream elements. Experts presented a range of solu-
tions including: regular pathology updates on diagnostic
criteria and thresholds; research into better prognostic
tools (such as biological markers of aggression); develop-
ment of more targeted / less harmful therapies, research
into less aggressive treatment regimes for low-risk lesions;
and patient-centred care for women with borderline le-
sions, relying on correlation between clinical, radiological
and pathological findings to make a diagnosis and plan
the management, rather than following set guidelines.
How experts used frames
Each expert used between one and four frames. Some
experts employed two or more moderately incommen-
surable frames, and were often conscious of inherent
contradictions. For example Expert #7 (clinician) used
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both the “stop squabbling in public” and “stop hiding
the problem” frames, acknowledging the possible incon-
sistency of this position. However, none of the experts’
discussions combined frames that were strongly incom-
mensurable, for example, no experts used both the “over-
diagnosis is harming women” and the “stop squabbling in
public” frames. The “stop hiding the problem” frame was
the most commonly used, and was adopted by experts
working across all roles except consumer representation/
advocacy. All (three) consumers working in advocacy roles
used the “stop squabbling in public” frame.
There were observable patterns between experts’ overall
views on breast screening and their use of overdiagnosis
frames. All experts who were critical of breast screening
used the “don’t hide the problem” frame, and none of
them used the “stop squabbling in public” frame. Experts
who were supportive of breast screening used one or
other, but not both, of these frames (in approximately
equal numbers), and were the only group to use the “stop
squabbling in public” frame. Further detail on this is avail-
able in Additional file 2: Table S1-S2).
Discussion
It is recognised in the breast screening literature that
experts hold differing opinions about overdiagnosis, but
the basis for those differences has not been explored.
We identified six overdiagnosis frames in use by Australian
breast screening experts and analysed the elements of
each frame. There was considerable variation between
frames, in terms of: how overdiagnosis was problematised,
what information was highlighted as being relevant, what
values were prioritised as being important, and what solu-
tions were suggested. These multiple points of difference
explain much of the controversy and disagreement that
surrounds this important topic.
To our knowledge, there has been no detailed empir-
ical study on what and how breast screening experts
think about overdiagnosis. Some journals have presented
debates containing opposing arguments as a way of ex-
ploring some of the diversity within this topic [25, 26].
Others have published letters to the editor in response
to controversial elements within breast screening articles
[27]. Our work builds upon and extends the existing
literature, providing a comprehensive analysis of the
frames used to talk about and understand overdiagnosis
in breast screening. Previous research has suggested that
consumers are largely unaware about overdiagnosis [12],
but nevertheless an important avenue for future research
would be to investigate whether women have pre-existing
ideas and concerns about aspects of overdiagnosis that
have not been captured within the frames presented here.
An understanding of the elements within different
overdiagnosis frames will help those who work in, or
consider participating in breast screening [28, 29]. The
different frames may be a useful scaffold upon which to
generate thoughtful discussion amongst practitioners.
These frames also offer new tools for experts to clarify
their own positions and to understand the opinions of
others on overdiagnosis including views on whether and
how it is a problem, and what solutions might be appro-
priate. This may facilitate recognition of points of agree-
ment and form a basis for co-operative dialogue in the
best interests of consumers [19]. Policy makers are faced
with a baffling array of suggestions about what, if any-
thing, should be done with regard to breast screening
overdiagnosis. The experts who participated in this study
offered a range of solutions, focusing on different points
along the screening journey, including primary research,
evidence translation and presentation, communication with
consumers, screening practices, diagnostic practices, and
treatment. By viewing these solutions in connection with
the frame to which they belong, it becomes easier to see
why one solution might be preferred over another, and by
whom. Any management plan or policy is likely to need
multiple solutions, and incommensurability between some
frames will necessitate compromises and negotiations.
This study benefits from the open qualitative method-
ology, which allowed us to explore a topic about which
there was little pre-existing knowledge. We were able to
access the views and opinions from a range of influential
individuals and expert stakeholders from different parts
of Australia. Its strength lies in the depth of its enquiry
and its ability to capture the complexity of the evidence
base and value judgements underlying the range of dif-
ferent views. As with much qualitative work, we cannot
make any predictions about the prevalence or pattern of
our results within the wider population, and this may be
a useful avenue for future survey research. While this
study was limited to the Australian setting, much of the
developed world has organised breast screening pro-
grams, comparable values, and access to the same body
of scientific evidence, and thus the findings are likely to
be broadly applicable across these countries. It is pos-
sible that experts who participated in our study were
somehow different from those who were invited but did
not participate. We sought to minimise any bias of this
sort by ensuring that we interviewed experts with a
range of attitudes to screening, and a wide variety of
professional roles and experience.
Conclusions
Our results demonstrate that experts approach overdiag-
nosis in various ways, see a range of issues and values at
stake, and are inclined to promote different solutions.
This may be an important contributor to the ongoing
controversy in this topic, and offers a new explanation
for why some debates about overdiagnosis are so heated.
The concept of experts using different frames when
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thinking and talking about overdiagnosis might be a use-
ful tool for those who are engaged in the topic, assisting
with communication and facilitating better understand-
ing of others’ viewpoints.
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